NCT02675829

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 131 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.

Conditions

• Solid Tumor Cancers
• Lung Cancer
• Bladder Cancer
• Urinary Tract Cancers

Interventions

Type	Name	Description
DRUG	ado-trastuzumab emtansine	Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

Timeline

• Start date: 2016-02-01
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2016-02-05
• Last updated: 2026-03-04

Locations

7 sites across 1 country: United States